CA 15.3 in nonmalignant liver diseases.
CA 15.3 is a recent tumor marker for a wide range of cancers that is usually used for monitoring breast carcinoma patients. This study was performed to evaluate CA 15.3 behaviour in 161 patients with benign diffuse hepatic diseases who underwent thorough clinical and biochemical evaluation. Abnormal serum levels of this antigen were found in 8.7% of the 161 patients, 11.6% of the 86 cirrhotics, and 5.3% of the 75 noncirrhotic patients. The correlation between CA 15.3 and certain parameters characteristic of liver diseases was checked. IgA showed the most relevant correlation (r = 0.39, p less than 0.00001) and in our series a normal level of IgA was practically determinant of normal CA 15.3 levels. Our results also support the role played by hepatocellular dysfunction in increasing levels of this antigen in spite of the low number of false-positive results. CA 15.3 can be used as a tumor marker in these patients at levels used for healthy subjects.
Collazos
J
J
Internal Medicine Service, Hospital de Galdacano, Vizcaya, Spain.
Genollá
J
J
Ruibal
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000378:metabolism; D008103:Liver Cirrhosis / Q000097:blood / Q000276:immunology; D008107:Liver Diseases / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D007070:Immunoglobulin A